Mammalian Cell Culture Market Report 2026

Mammalian Cell Culture Market Overview

• Mammalian Cell Culture market size has reached to $4.86 billion in 2025 • Expected to grow to $8.13 billion in 2030 at a compound annual growth rate (CAGR) of 10.8% • Growth Driver: Rising Demand For Personalized Medicine Driving The Growth Of The Market Due To Its Role In Developing Patient-specific And Precision Therapies • Market Trend: Advancements In Two-Part Media Systems Accelerating Therapeutic Protein Production • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mammalian Cell Culture Market?

Mammalian cell culture is the process of growing animal cells under controlled laboratory conditions outside their natural environment. It involves maintaining cells in a nutrient-rich medium that provides essential growth factors, gases, and conditions such as temperature and pH. This technique is widely used in research, biotechnology, and medicine for studying cell biology, producing vaccines, and testing drugs. It allows scientists to mimic in vivo conditions and observe cellular behavior in a controlled setting. The main products of mammalian cell culture are media, sera, reagents, and equipment. Media refers to nutrient-rich solutions formulated to support the growth, proliferation, and maintenance of mammalian cells under controlled laboratory conditions. The key cell lines used include Chinese hamster ovary (CHO), Wistar Institute-38 (WI-38), rat glial tumor cell line (C6), human embryonic kidney 293 (HEK293), and henrietta lacks (HeLa). Major applications include biopharmaceutical production, vaccine production, toxicity testing, drug screening and development, and tissue engineering and regenerative medicine, with primary end users being pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, research and academic institutes, and contract research organizations (CROs).

What Is The Mammalian Cell Culture Market Growth Forecast?

The mammalian cell culture market size is expected to see rapid growth in the next few years. It will grow to $8.13 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increasing investments in cell and gene therapy, rising demand for biologics production, expansion of regenerative medicine research, growing focus on scalable cell culture technologies, increasing adoption of continuous bioprocessing. Major trends in the forecast period include increasing adoption of serum-free mammalian cell culture media, rising demand for large-scale biopharmaceutical production, growing use of automated cell culture systems, expansion of cell-based vaccine manufacturing, enhanced focus on process consistency and yield optimization.

Global Mammalian Cell Culture Market Segmentation

1) By Product: Media, Sera, Reagents, Equipment 2) By Cell Line: Chinese Hamster Ovary (CHO), Wistar Institute-38 (WI-38), Rat Glial Tumor Cell Line (C6), Human Embryonic Kidney 293 (HEK293), Henrietta Lacks (HeLa) 3) By Application: Biopharmaceutical Production, Vaccine Production, Toxicity Testing, Drug Screening and Development, Tissue Engineering And Regenerative Medicine 4) By End-Use: Pharmaceutical And Biotechnology Companies, Hospitals And Diagnostic Laboratories, Research And Academic Institutes, Contract Research Organizations (CROs) Subsegments: 1) By Media: Serum-free Media, Chemically Defined Media, Classical Media, Protein-free Media, Specialty Media, Custom Media Formulations 2) By Sera: Fetal Bovine Serum (FBS), Newborn Calf Serum, Adult Bovine Serum, Donor Horse Serum 3) By Reagents: Growth Factors And Cytokines, Cell Dissociation Reagents, Supplements And Additives, Cryoprotective Agents, Buffers And Salt Solutions, Antibiotics And Antimycotics 4) By Equipment: Bioreactors And Fermenters, Culture Vessels, Filtration Systems, Centrifuges, Cell Counters And Analyzers, Incubators, Biosafety Cabinets, Microscopes, Refrigeration And Cryostorage Equipment

What Is The Driver Of The Mammalian Cell Culture Market?

The increasing demand for personalized medicine is expected to propel the growth of the mammalian cell culture market going forward. Personalized medicine customizes medical treatment based on a patient’s genetic, environmental, and lifestyle factors for more effective and precise care. The rise in demand for personalized medicine is driven by improved treatment effectiveness, as it tailors therapies to individual genetic and biological profiles, enhancing patient outcomes. Mammalian cell culture enables personalized medicine by providing a controlled environment to study patient-specific cells, allowing the development of tailored therapies and testing of drug responses for more precise and effective treatments. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the mammalian cell culture industry.

Key Players In The Global Mammalian Cell Culture Market

Major companies operating in the mammalian cell culture market are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, GE Healthcare, Becton Dickinson and Company, Lonza Group AG, Avantor Inc., Agilent Technologies Inc., Charles river laboratories, Sartorius AG, Samsung biologics, Wuxi biologics, Bio-Techne Corporation, Miltenyi Biotec, STEMCELL Technologies, Takara Bio Inc., Goodwin biotechnology, HiMedia Laboratories Private Limited, Promocell GmbH, Eppendorf AG, Cell Culture Company LLC, Cell X Technologies.

Global Mammalian Cell Culture Market Trends and Insights

Major companies operating in the mammalian cell culture market are focusing on innovation in cell culture media, such as two-part production systems, to enhance protein yield, improve cell viability, and streamline scalable bioprocess workflows for therapeutic applications. A two-part production system is a cell culture approach that uses two distinct media components, one to support general cell growth and another to enhance protein expression, enabling improved productivity. For instance, in July 2023, Lonza Group Ltd., a Switzerland-based contract development and manufacturing organization (CDMO), launched the TheraPRO CHO Media System. This innovative platform is a chemically defined, animal-component-free cell culture media designed specifically for GS-CHO mammalian cell lines. The system aims to enhance the production of therapeutic proteins and monoclonal antibodies by providing higher cell viability and improved protein yields. Its scalable design supports all stages of bioprocess manufacturing, from cell line development to large-scale production. With this launch, Lonza seeks to streamline workflows, improve product quality, and accelerate time-to-market for biopharmaceutical manufacturers.

What Are Latest Mergers And Acquisitions In The Mammalian Cell Culture Market?

In December 2024, Merck KGaA, a Germany-based science and technology company, acquired HUB Organoids Holding B.V. for an undisclosed amount. With this acquisition, Merck aims to advance its next-generation biology portfolio by integrating HUB’s organoid technology to accelerate drug discovery, expand 3D cell-culture capabilities, and provide human-relevant models for disease modeling and toxicity testing. HUB Organoids Holding B.V. is a Netherlands-based biotechnology company specializing in mammalian cell culture–based organoid models that replicate human organ structure and function for research and therapeutic applications.

Regional Outlook

North America was the largest region in the mammalian cell culture market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Mammalian Cell Culture Market?

The mammalian cell culture market consists of sales of media, sera, reagents, equipment, bioreactors, culture plates, flasks, incubators, centrifuges, and microscopes. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mammalian Cell Culture Market Report 2026?

The mammalian cell culture market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mammalian cell culture industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.